Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Graeff

Showing results (141-150 of 206) with videos related to

Pageof 21
Sort By:
The Journal of Biological Chemistry|May 29, 1999
Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factorS Ried, C Jäger, M Jeffers, et al.
Electrophoresis|May 1, 1997
Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancerB Türkmen, M Schmitt, B Schmalfeldt, et al.
Biomedica Biochimica Acta|January 1, 1991
Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancerM Schmitt, L Goretzki, F Jänicke, et al.
FEBS Letters|September 11, 1989
Elastase released from human granulocytes stimulated with N-formyl-chemotactic peptide prevents activation of tumor cell prourokinase (pro-uPA)M Schmitt, N Kanayama, A Henschen, et al.
Geburtshilfe Und Frauenheilkunde|February 1, 1996
-Intravenous or oral etoposide therapy of platinum refractory ovarian cancer with early recurrence. Results of a prospective randomized study-W Kuhn, B Schmalfeldt, J Dose, et al.
Methods in Molecular Medicine|February 23, 2011
RFLP Molecular Analysis of the Urokinase-Type Plasminogen Activator GeneB Muehlenweg, A Schnelzer, B Türkmen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 1995
Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancerC Thomssen, M Schmitt, L Goretzki, et al.
British Journal of Cancer|January 1, 1997
Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancerM Schmitt, C Thomssen, K Ulm, et al.
Cancer|October 15, 1992
Radical surgical procedure improves survival time in patients with recurrent ovarian cancerF Jänicke, M Hölscher, W Kuhn, et al.
European Journal of Biochemistry|January 23, 1999
Rel transcription factors contribute to elevated urokinase expression in human ovarian carcinoma cellsU Reuning, L Guerrini, T Nishiguchi, et al.
Pageof 21

Showing results (141-150 of 206) with videos related to

Sort By:
Pageof 21
The Journal of Biological Chemistry|May 29, 1999
Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factorS Ried, C Jäger, M Jeffers, et al.
Electrophoresis|May 1, 1997
Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancerB Türkmen, M Schmitt, B Schmalfeldt, et al.
Biomedica Biochimica Acta|January 1, 1991
Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancerM Schmitt, L Goretzki, F Jänicke, et al.
FEBS Letters|September 11, 1989
Elastase released from human granulocytes stimulated with N-formyl-chemotactic peptide prevents activation of tumor cell prourokinase (pro-uPA)M Schmitt, N Kanayama, A Henschen, et al.
Geburtshilfe Und Frauenheilkunde|February 1, 1996
-Intravenous or oral etoposide therapy of platinum refractory ovarian cancer with early recurrence. Results of a prospective randomized study-W Kuhn, B Schmalfeldt, J Dose, et al.
Methods in Molecular Medicine|February 23, 2011
RFLP Molecular Analysis of the Urokinase-Type Plasminogen Activator GeneB Muehlenweg, A Schnelzer, B Türkmen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 1995
Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancerC Thomssen, M Schmitt, L Goretzki, et al.
British Journal of Cancer|January 1, 1997
Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancerM Schmitt, C Thomssen, K Ulm, et al.
Cancer|October 15, 1992
Radical surgical procedure improves survival time in patients with recurrent ovarian cancerF Jänicke, M Hölscher, W Kuhn, et al.
European Journal of Biochemistry|January 23, 1999
Rel transcription factors contribute to elevated urokinase expression in human ovarian carcinoma cellsU Reuning, L Guerrini, T Nishiguchi, et al.
Pageof 21